295 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
What's in Store for Vertex (VRTX) This Earnings Season? http://www.zacks.com/stock/news/398972/whats-in-store-for-vertex-vrtx-this-earnings-season?cid=CS-ZC-FT-398972 Apr 24, 2019 - On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
What's in the Cards for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/398903/whats-in-the-cards-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-398903 Apr 24, 2019 - Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock? http://www.zacks.com/stock/news/398878/trevena-trvn-to-post-q1-earnings-what-awaits-the-stock?cid=CS-ZC-FT-398878 Apr 24, 2019 - During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? http://www.zacks.com/stock/news/392203/whats-in-the-cards-for-astrazeneca-azn-in-q1-earnings?cid=CS-ZC-FT-392203 Apr 23, 2019 - AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release http://www.zacks.com/stock/news/392470/incyte-incy-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release?cid=CS-ZC-FT-392470 Apr 23, 2019 - Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap http://www.zacks.com/stock/news/390936/the-zacks-analyst-blog-highlights-commscope-ceridian-hcm-cabot-oil-gas-incyte-and-snap?cid=CS-ZC-FT-390936 Apr 23, 2019 - The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? http://www.zacks.com/stock/news/390180/exact-sciences-exas-to-post-q1-earnings-whats-in-store?cid=CS-ZC-FT-390180 Apr 22, 2019 - During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season? http://www.zacks.com/stock/news/390036/is-a-beat-in-store-for-abbvie-abbv-this-earnings-season?cid=CS-ZC-FT-390036 Apr 22, 2019 - Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
5 Must-Buy Stocks Amid Exaggerated Economic Slowdown http://www.zacks.com/stock/news/389800/5-must-buy-stocks-amid-exaggerated-economic-slowdown?cid=CS-ZC-FT-389800 Apr 22, 2019 - The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.

Pages: 123456789101112...30

<<<Page 7>